

# Structural and biophysical analysis of a *Haemophilus influenzae* tripartite ATP-independent periplasmic (TRAP) transporter

Michael J. Currie<sup>1†</sup>, James S. Davies<sup>1,2†</sup>, Mariafrancesca Scalise<sup>3</sup>, Ashutosh Gulati<sup>2</sup>, Joshua D. Wright<sup>1</sup>, Michael C. Newton-Vesty<sup>1</sup>, Gayan S. Abeysekera<sup>1</sup>, Ramaswamy Subramanian<sup>4</sup>, Weixiao Y. Wahlgren<sup>5</sup>, Rosmarie Friemann<sup>6</sup>, Jane R. Allison<sup>7</sup>, Peter D. Mace<sup>8</sup>, Michael D.W. Griffin<sup>9</sup>, Borries Demeler<sup>10,11</sup>, Soichi Wakatsuki<sup>12,13</sup>, David Drew<sup>2</sup>, Cesare Indiveri<sup>3</sup>, Renwick C.J. Dobson<sup>1,9\*</sup> & Rachel A. North<sup>2\*</sup>

<sup>1</sup> Biomolecular Interaction Centre, Maurice Wilkins Centre for Biodiscovery, MacDiarmid Institute for Advanced Materials and Nanotechnology, and School of Biological Sciences, University of Canterbury, PO Box 4800, Christchurch 8140, New Zealand.

<sup>2</sup> Department of Biochemistry and Biophysics, Stockholm University, 106 91 Stockholm, Sweden.

<sup>3</sup> Department DiBEST (Biologia, Ecologia, Scienze della Terra) Unit of Biochemistry and Molecular Biotechnology, University of Calabria, Via P. Bucci 4C, 87036 Arcavacata di Rende, Italy.

<sup>4</sup> Biological Sciences and Biomedical Engineering, Bindley Bioscience Center, Purdue University, 1203 W State St, West Lafayette, IN 47906, USA.

<sup>5</sup> Department of Chemistry and Molecular Biology, Biochemistry and Structural Biology, University of Gothenburg, Box 462, 40530 Gothenburg, Sweden.

<sup>6</sup> Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Box 440, 40530 Gothenburg, Sweden.

<sup>7</sup> Biomolecular Interaction Centre, Digital Life Institute, Maurice Wilkins Centre for Molecular Biodiscovery, and School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand.

<sup>8</sup> Biochemistry Department, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.

<sup>9</sup> Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Victoria 3010, Australia.

<sup>10</sup> Department of Chemistry and Biochemistry, University of Montana, Missoula, MT, USA.

<sup>11</sup> Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, AB, Canada.

<sup>12</sup> Biological Sciences Division, SLAC National Accelerator Laboratory, Menlo Park, CA 94025, USA.

<sup>13</sup> Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.

<sup>†</sup>These authors contributed equally to this work

\*For correspondence

<sup>32</sup> [rachel.north@dbb.su.se](mailto:rachel.north@dbb.su.se) or [renwick.dobson@canterbury.ac.nz](mailto:renwick.dobson@canterbury.ac.nz)

**Keywords:** sialic acid, Neu5Ac, protein-protein interaction, membrane transport proteins, transport mechanism

## Abstract

36 Tripartite ATP-independent periplasmic (TRAP) transporters are secondary-active transporters that  
receive their substrates via a soluble binding protein to move bioorganic acids across bacterial or  
38 archaeal cell membranes. Recent cryo-EM structures of TRAP transporters provide a broad  
framework to understand how they work, but the mechanistic details of transport are not yet defined.  
40 Here we report the cryo-EM structure of the *Haemophilus influenzae* *N*-acetylneuraminate TRAP  
transporter (*HiSiaQM*) at 2.99 Å resolution (extending to 2.2 Å at the core), revealing new features.  
42 The improved resolution (the previous *HiSiaQM* structure is 4.7 Å resolution) permits accurate  
assignment of two  $\text{Na}^+$  sites and the architecture of the substrate binding site, consistent with  
44 mutagenic and functional data. Moreover, rather than a monomer, the *HiSiaQM* structure is a  
homodimer. We observe lipids at the dimer interface, as well as a lipid trapped within the fusion that  
46 links the SiaQ and SiaM subunits. We show that the affinity ( $K_D$ ) for the complex between the soluble  
*HiSiaP* protein and *HiSiaQM* is in the micromolar range and that a related SiaP can bind *HiSiaQM*.  
48 This work provides key data that enhances our understanding of the ‘elevator-with-an-operator’  
mechanism of TRAP transporters.

50

(197 words)

## Introduction

52 Secondary-active transporters are found in all domains of life (1-3). They catalyse the movement of  
53 molecules across membranes, exploiting the free energy associated with electrochemical ion  
54 gradients to drive transport [see (4,5) for recent reviews on the topic]. In bacteria, secondary-active  
55 transporters are used for both the export of toxic compounds and for the import of nutrients needed  
56 for cell growth (4,6).

58 The import of carbohydrates across the plasma membrane is a key process for bacteria, particularly  
59 those pathogenic bacteria that adopt a scavenging lifestyle within their host (7). For *Haemophilus*  
60 *influenzae*, a Gram-negative opportunistic pathogen, the ability to uptake host-derived sialic acids is  
61 important for pathogenesis (8). Sialic acids are a diverse family of nine-carbon carbohydrates, and  
62 in humans, sialic acids are highly abundant in the respiratory and gastrointestinal tracts where they  
63 coat glycoconjugates as terminal sugars (7,9). The most common sialic acid found in humans is *N*-  
64 acetylneuraminate (Neu5Ac) (7). To gain a growth advantage in these environments, bacteria such  
65 as *H. influenzae* evolved the ability to utilise host-derived sialic acid as a nutrient source (**Figure 1**).  
66 The sialic acid catabolic pathway provides an alternative source of carbon, nitrogen and energy, and  
67 has been identified in 452 bacterial species, most of which are mammalian pathogens or commensals  
68 (10). Alongside degradation, and perhaps more importantly, *H. influenzae* uses sialic acids to coat  
69 its lipopolysaccharide surface, and this sialylation in turn provides camouflage and protection from  
70 the human immune response (11,12). *H. influenzae* lacks the *de novo* sialic acid biosynthetic  
71 pathway, so sialic acids must be scavenged and transported into the cell (13). Engineered *H.*  
72 *influenzae* strains that are unable to transport sialic acids into the cell have decreased virulence in  
73 animal models—evidence that the sialic acid transport pathway is a viable therapeutic target (14) and  
74 others have already developed inhibitors to sialic acid transporters (15). The sole sialic acid  
75 transporter in *H. influenzae* belongs to the tripartite ATP-independent periplasmic (TRAP)  
76 transporter family.

### 76 (Insert Figure 1)

78 Tripartite ATP-independent periplasmic (TRAP) transporters are a major class of secondary-active  
79 transporters found only in bacteria and archaea (16,17). They use energetically favourable cation  
80 gradients to drive the import of specific carboxylate-containing nutrients against their concentration-  
81 gradient, including C<sub>4</sub>-dicarboxylates,  $\alpha$ -keto acids, aromatic substrates, amino acids and sialic acids  
82 (18). A functional TRAP system is made up of a soluble substrate-binding ‘P-subunit’, and a  
membrane-bound complex comprising a small ‘Q-subunit’ and a large ‘M-subunit’. For most TRAP

transporters the Q- and M-subunits are separate polypeptides (19,20), but in ~25% of sequences [InterPro analysis (21)] the Q- and M-subunit polypeptides are fused into a single polypeptide (16). TRAP transporters are different from almost all other secondary-active transporters in that they can only accept substrates from the P-subunit (22). Analogous to ABC importers, the P-subunit is secreted into the periplasm to capture host-derived substrates with high affinity and specificity. The substrate-loaded P-subunit subsequently delivers the substrate to the membrane transporter (Q- and M-subunits) (18,23-25).

The SiaPQM system from *H. influenzae* has fused Q- and M-subunits and is one of the best characterised TRAP systems to date (11,23,24,26,27), with key functional and biophysical studies informing a putative transport mechanism driven by a  $\text{Na}^+$  gradient (28). Before transport into the cell by SiaPQM, sialidases release sialic acids from the terminal position of host glycoconjugates (Figure 1). *H. influenzae* is, however, sialidase negative and relies on the sialidases of other bacteria to generate free sialic acids (29). In Gram-negative bacteria, sialic acids diffuse into the periplasm through an outer membrane porin, such as the general porins OmpF or OmpC in many bacteria, OmpP2 in *H. influenzae* (30,31), or by using a Neu5Ac specific porin such as NanC (32). The substrate-binding protein SiaP (P-subunit) binds Neu5Ac in the periplasm with high-affinity, undergoing a ligand-induced conformational change to a closed state (23-26). It is this closed form that then delivers Neu5Ac to the membrane bound Q- and M-subunits. This protein-protein interaction and the subsequent transport of Neu5Ac through the transmembrane subunits are not yet characterised. In particular, the conformational changes that take place for both SiaP and SiaQM to allow alternating access of the transporter have not been fully elucidated, though we have suggested previously that the binding of the closed P-subunit must induce either a global elevator-type motion or a local gating rearrangement as a part of an elevator mechanism (33). These changes allow the transporter to bind Neu5Ac and  $\text{Na}^+$  at the periplasmic side and transport them into the cytoplasm.

Here, we report the high-resolution cryo-EM structure of *HiSiaQM* in amphipol and demonstrate that in detergent, amphipol and a nanodisc environment the fused *H. influenzae* SiaQM membrane subunits can stably exist as both monomeric (QM) and homodimeric (2QM) states. We determined the homodimeric (2QM) structure of *HiSiaQM* using single particle cryo-electron microscopy, the first structure of a fused TRAP transporter at near atomic resolution (2.99 Å, with local resolution extending to ~2.2 Å), which reveals new details of the transport mechanism. The structure, combined with functional and biophysical data, supports the hypothesis that *HiSiaQM* operates using the ‘elevator-with-an-operator’ mechanism that we proposed for TRAP transporters (33).

## Results

116 *The cryo-EM structure of HiSiaQM reveals a dimeric configuration.*

We assessed the stability of *HiSiaQM* in several detergents that solubilise *HiSiaQM* from *Escherichia coli* membranes. Lauryl maltose neopentyl glycol (L-MNG) led to more stable protein preparations compared to dodecyl- $\beta$ -D-maltoside (DDM) (**Supplementary Figure 1a**), which has been used previously (20,27). Curiously, *HiSiaQM* purified with a high L-MNG concentration elutes as a major peak at 65 mL with a significant shoulder at 58 mL and this elution profile is reversed at a low L-MNG concentration (**Supplementary Figure 1a**)—a signature of a self-association, suggesting *HiSiaQM* forms higher order oligomers. By comparison, the non-fused monomeric *Photobacterium profundum* SiaQM (*PpSiaQM*) does not show this behaviour when expressed with the same purification tag and purified in the same low concentration of L-MNG, eluting at 67 mL, which we have previously shown to correspond to a monomeric species (33) (**Supplementary Figure 1a**).

We decided to purify *HiSiaQM* using L-MNG under conditions that favour the larger species for the following reasons: 1) we were previously unsuccessful at determining the cryo-EM structure of the monomer, because of the small size of the protein (72 kDa) and lack of features outside of the micelle or nanodisc that makes particle alignment difficult; 2) even with a megobody bound to increase the size and provide asymmetric features, other structural investigation on monomeric *HiSiaQM* led to only moderate resolution data, which may reflect some instability or heterogeneity in the sample; and 3) we reasoned that avoiding fiducial markers such as nanobodies and megabodies would also allow exploration of the conformational dynamics of the transporter without any binder-associated bias. Thus, the larger *HiSiaQM* species was isolated by exchanging purified protein out of L-MNG detergent and into amphipol A8-35, an amphipathic polymer used to solubilise and stabilise membrane proteins.

*HiSiaQM* comprises two distinct dimeric configurations in approximately equal quantities (36%) in the 14,281-image dataset (**Figure 2a, Supplementary Figure 2, Supplementary Table 1**). Dimeric *HiSiaQM* exists either as a side-by-side parallel dimer where both monomers face the same way, or an antiparallel dimer where one monomer is rotated around the dimer interface 180° relative to the other (**Figure 2a, Supplementary Figure 2**). Dimerisation is mediated by the same interface in both of these structures but given that *HiSiaP* is found in the periplasm and SiaQM requires SiaP to function, the parallel dimer is almost certainly the physiologically relevant conformation. The maps are of high resolution (overall 2.9 Å for the antiparallel dimer and 3.2 Å for the parallel dimer, FSC = 0.143 criterion) with both extending to 2.2 Å at the core, allowing for accurate fitting of helices and

148 (almost) all side chains (**Supplementary Figure 3**). The dimeric particles allowed for structure  
149 determination without a protein fiducial marker bound (e.g., nanobody or antigen-binding fragment),  
150 which was required to solve the structure of the monomeric *PpSiaQM* (33) and the lower resolution  
monomeric *HiSiaQM* (27).

### (Insert Figure 2)

152 In all four *HiSiaQM* protomers the transport domain is in the inward-open conformation ('elevator  
153 down'), which is the substrate release state (r.m.s.d. for alignment = ~0.2 Å, **Figure 2a,b**). This is  
154 the same conformation as the previous megobody-bound *PpSiaQM* structures in amphipol and a  
155 nanodisc (33) and also the same as the recently reported lower resolution (4.7 Å) megobody-bound  
156 *HiSiaQM* structure in a nanodisc (27). Three-dimensional variability analysis (3DVA) (34) of our  
157 *HiSiaQM* reconstructions shows only very subtle motion at the dimer interface, and does not show  
158 any global elevator motions in the final reconstruction (**Supplementary Movie 1**). That we observe  
159 the inward-open conformation without either a bound P-subunit or fiducial marker, suggests that this  
160 is the resting state of the transporter under experimental conditions (in the absence of a membrane  
bilayer, membrane potential and chemical gradients).

162 Both dimers form through an interface between the Q-subunits of the monomers. The relatively flat  
163 sides of the Q-subunits are positioned adjacent to each other in an interface that is not intimately  
164 connected by side chain interactions (**Figure 2a**). When refined using dimeric masks, the parallel  
165 dimer has slightly lower resolution at the dimer interface (scaffold region), compared to the  
166 antiparallel dimer. Local refinement of each monomer within the parallel dimer improved the  
167 resolution at the scaffold region, suggesting this is perhaps a relatively dynamic interface. The buried  
168 interface area is small (~200 Å<sup>2</sup>) for the antiparallel configuration, and even smaller (~100 Å<sup>2</sup>) for  
169 the parallel configuration (35). Further still, the parallel interface area is formed by a small number  
170 of residues at the N-termini, which have modest resolution. The majority of the interface for these  
171 dimers must therefore be mediated by lipid molecules that bridge between the monomers, some of  
172 which we observe directly in the cryo-EM maps (discussed later). Small interfaces have been  
173 observed in the elevator-type Na<sup>+</sup>/H<sup>+</sup> antiporter NhaA from *E. coli* (36) and throughout the SLC26  
174 family (37) (also elevator-type), but the *HiSiaQM* interfaces are much smaller than other dimeric ion  
175 transporter superfamily members, such as the TRAP related symporter VcINDY, a divalent anion/Na<sup>+</sup>  
176 symporter (DASS) from *Vibrio cholerae* (38-40), and the antimicrobial efflux pumps MtrF (41) and  
YdaH (42), which are all elevator-type homodimers with buried interface areas of ~1800–2100 Å<sup>2</sup>.

178 The topology of *HiSiaQM* is similar to the non-fused *PpSiaQM*, aside from the additional fusion  
helix that links the Q- and M-subunits across the membrane (**Figure 2c**). The helix starts on the

180 cytoplasmic side, packing against the Q-subunit and crossing the membrane vertically, then turns 90°  
182 and runs laterally (perpendicular to the membrane) before forming a loop and connecting to the M-  
184 subunit on the periplasmic side (**Figure 2a-c**). An overlay with the recently determined SiaQM  
186 structures shows that the main chains are similar (*PpSiaQM* to high resolution *HiSiaQM* r.m.s.d. = 1.2 Å across 520 C<sub>α</sub>-atoms and lower resolution *HiSiaQM* to high resolution *HiSiaQM* r.m.s.d. = 1.0 Å across 571 C<sub>α</sub>-atoms, **Figure 2d**). All three structures are in the ‘elevator down’ conformation with close alignment between the 16-17 helices (**Figure 2d**). Differences in the loops of the proteins exist, including the positioning of the ‘clamshell’ loops of the Na<sup>+</sup> binding sites (discussed later).

188 *HiSiaQM exists in a stable monomer-dimer self-association.*

190 The oligomeric assembly of TRAP transporters within the membrane has implications for the transport cycle, as well as the interaction between SiaP and SiaQM. Secondary-active transporters can exist as monomers (43,44), or as larger multimeric complexes of oligomers (45,46). For example, 192 VcINDY (38-40), MtrF (41) and YdaH (42) all share the same fold and have a dimeric structure (47). These elevator-type transporters form oligomers at the scaffold domains, which is thought to provide 194 the stability needed for elevator movements of the transport domain. Recently, a TRAP related fused transporter belonging to the TAXI (TRAP-Associated eXtracytoplasmic Immunogenic proteins) 196 TRAP subfamily from *Proteus mirabilis* also eluted as two peaks during size exclusion chromatography, signalling a likely self-association (48). In contrast, the non-fused TRAP 198 transporter *PpSiaQM* uniquely functions as a monomer (1QM) (33), where instead of homodimerisation, the scaffold is formed by heterodimerisation of the Q- and M-subunits. Recent 200 work on *HiSiaQM* also proposes a monomeric (1QM) functional transporter (20,27). However, our 202 high resolution dimeric cryo-electron microscopy structures and the self-association behaviour observed from size exclusion chromatography (**Supplementary Figure 1a**) infer a stable dimeric architecture for *HiSiaQM* is possible.

204 To further support this result, *HiSiaQM* purified in L-MNG and DDM was characterised by sedimentation velocity analytical ultracentrifugation (SV-AUC), resulting in two distinct species in 206 each of the samples (**Figure 3a**, **Supplementary Figure 4-6**). As there were no contaminants following purification (**Supplementary Figure 1b**), the two species represent a protein self- 208 association, consistent with that observed during purification. The oligomeric state of the two species was verified using SV-AUC analysis that compares the measured masses with theoretical masses. 210 This suggests that *HiSiaQM* is present as a monomer and a dimer in both L-MNG (**Figure 3a**) and DDM (**Supplementary Figure 4**). The two species have sedimentation coefficients (all are corrected 212 for water and 20 °C unless otherwise specified) of 7.3 S and 9.9 S in L-MNG, and 7.6 S and 10.3 S

in DDM. The calculated frictional ratios for the monomeric species are 1.2 in L-MNG and 1.1 in  
214 DDM. These are consistent with a globular particle, as we would expect for a protein in a detergent  
216 micelle. The calculated frictional ratios for the dimeric species are 1.2 in L-MNG and 1.0 in DDM,  
which are also consistent with a globular particle.

### (Insert Figure 3)

218 We then solubilised *HiSiaQM* in amphipol (A8-35) and nanodiscs (cNW11, ~11 nm in diameter (49))  
219 to ascertain whether these systems might afford better stability and again found two species consistent  
220 with a monomer and a dimer. SV-AUC analysis of amphipol solubilised protein (**Figure 3b**) is  
221 consistent with a monomer at 5.9 S and a dimer at 8.3 S, when considering the oligomeric information  
222 obtained from SV-AUC in L-MNG (**Figure 3a**). In nanodiscs, a reconstitution ratio of 1:4:80 of  
223 *HiSiaQM*:MSP:lipid (MSP = membrane scaffold protein) resulted in multiple peaks during size  
224 exclusion chromatography (**Supplementary Figure 7a**). Three fractions across the elution profile  
225 were analysed with SV-AUC and the main species in each had sedimentation coefficients of 4.0 S,  
226 6.8 S, and 9.0 S (**Supplementary Figure 7b**). The species at 4.0 S is most consistent with empty  
227 nanodiscs and the species at 6.8 S and 9.0 S are most consistent with nanodiscs containing monomeric  
228 and dimeric *HiSiaQM*, respectively (**Supplementary Figure 7b**).

230 To summarise, we have demonstrated that *HiSiaQM* can exist in a monomer-dimer state in two  
231 detergents, amphipol and nanodiscs, which mimic the native environment. The proposal that  
232 *HiSiaQM* forms dimers within the plasma membrane is supported by the observation that a stable  
233 dimer with low aggregation propensity forms when solubilised in L-MNG (**Supplementary Figure**  
234 **1a**, blue trace). Stable species also exist when solubilised in amphipol (**Figure 3b**), particularly  
235 evidenced by the collection of cryo-EM data to <3 Å resolution. Under the same L-MNG detergent  
236 conditions, similar concentrations, and with an identical Ni<sup>2+</sup> affinity tag, non-fused *PpSiaQM* does  
237 not show this behaviour (**Supplementary Figure 1a**)—evidence that dimerisation is a result of a self-  
238 association and not the Ni<sup>2+</sup> affinity tag or cohabitation, where the number of available micelles is  
239 low enough that two proteins cohabit the same micelle for stable solubilisation. The dimeric  
240 assembly of *HiSiaQM* is consistent with other examples of transporters that use the elevator-type  
mechanism (e.g., VcINDY (38-40)), but clearly different from that reported recently for *PpSiaQM*  
and *HiSiaQM* TRAP transporters (27,33).

242 *Lipid binding sites.*

243 As a transporter, *HiSiaQM* has evolved alongside lipids, which are increasingly shown to be  
244 important for general transporter function and oligomerisation (50-52). Evident in our cryo-EM maps

are well-defined phospholipid densities associated with areas of *HiSiaQM* that may be important for  
246 the function of an elevator-type mechanism (**Figure 4**), but require further testing. The two most compelling areas are the dimer interface and a lipid binding pocket formed by the fusion helix.

248 There is a void region at the dimer interface in both structures that likely contains amphipol polymers and lipids. Indeed, we observe density for lipids in this region (best seen in the slightly higher  
250 resolution antiparallel dimer) (**Figure 2a**, **Figure 4b**). Notably, these densities are adjacent to tryptophan residues (**Supplementary Figure 8**), known for their role in anchoring membrane  
252 proteins (53), and one of the positions is where we also observe clear lipid density in the *PpSiaQM* structure in a nanodisc (33). The discovery of these annular lipids is surprising given that the protein  
254 was first extracted and extensively purified in L-MNG detergent, followed by exchange into A8-35 amphipol for cryo-EM studies. There are some weaker densities around the periphery of the protein  
256 that likely correspond to amphipol, but we can confidently identify densities for phospholipids given their distinctive hairpin shape (**Figure 4**). That lipids have remained bound in this area through the  
258 isolation and purification supports that these are strong interactions, which thereby anchor the scaffold domain in the membrane. The lipids at this interface may also have a role in strengthening  
260 dimerisation, as seen in other secondary-active transporters such as NhaA (36,51).

#### (Insert Figure 4)

262 The architecture of the fusion helix leaves a pocket between the lateral part of the helix and the main  
264 bundle of the transporter. A closer inspection of the map density shows that a distinct hairpin-shaped  
266 phospholipid density is positioned in this pocket (**Figure 4c**). This enclosed pocket appears to tightly  
268 fit only one phospholipid, which is presumably trapped here during protein folding. Several residues  
270 from the scaffold portion are well-poised to interact with a lipid headgroup, including H100, R104, K178 and W227 (**Figure 4c**). Analysis of the electrostatic surface of the pocket shows a significant  
amount of positive charge. We suggest that this site likely binds a negatively charged phospholipid  
and have modelled phosphatidylglycerol into the density. The predicted interacting residues are not  
well conserved amongst fused TRAP transporters (**Supplementary Figure 8**), which is possibly a  
reflection of varying bacterial membrane compositions.

272 This site and the presence of a lipid were not identified in the recent structure of *HiSiaQM* in a  
274 nanodisc (containing only the zwitterionic lipid DMPC)—instead, amino acids are modelled to fill  
the hydrophobic pocket. This is notable, as Peter et al. (27) hypothesised that W227 is important for  
276 the SiaP:SiaQM interaction, and show that mutation of this residue to an arginine significantly affects  
bacterial growth in an *in vivo* growth assay. The resolution of our structures allows us to unambiguously model this residue facing away from the surface and engaged in an interaction with

278 the trapped phospholipid, further supporting our identification of tryptophan residues in anchoring  
280 roles in the scaffold of TRAP transporters (33). This finding is important in the context of the  
282 transport mechanism used by *HiSiaPQM*. As the identified phospholipid is intercalated between  
284 scaffolding helices and is very close to the putative SiaP:SiaQM interface, it is feasible that this site  
286 is physiologically significant and may influence the stability of the transporter or even the  
288 conformational dynamics of the entire system. The fusion helix and concomitant lipid molecule may  
290 provide a more structurally rigid scaffold than a Q-M heterodimer, *i.e.*, *PpSiaQM*, although how this  
impacts the elevator transition requires further testing. While this binding pocket is likely found in a  
number of fused TRAPs (based on sequence predictions *e.g.*, *FnSiaQM* and *AaSiaQM* in  
**Supplementary Figure 8**), it is not clear whether they also bind lipids here without experimental  
data. We emphasise that this phospholipid binding pocket is not present in *PpSiaQM*, which may  
point to differences in the dynamics of the scaffolds and how the scaffold interacts with SiaP in non-  
fused systems.

#### *Neu5Ac and Na<sup>+</sup> binding sites.*

292 Although others have already demonstrated Neu5Ac transport for the *HiSiaPQM* system (28), we  
294 verified that our recombinant *HiSiaPQM* is active after solubilisation in the previously untested  
detergent L-MNG. Time-dependent uptake of [<sup>3</sup>H]-Neu5Ac was measured after reconstituting  
296 *HiSiaQM* into potassium containing proteoliposomes (**Figure 5a**). This method allows for the  
transport dependence on a Na<sup>+</sup> gradient ( $\Delta\mu\text{Na}^+$ , generated by adding external Na<sup>+</sup>) or a membrane  
potential ( $\Psi$ , generated by adding valinomycin) to be measured (54).

#### **298 (Insert Figure 5)**

300 Transport by *HiSiaQM* was dependent on a Na<sup>+</sup> gradient ( $\Delta\mu\text{Na}^+$ ) (**Figure 5a**, green and orange  
302 circles) and was stimulated 3-fold in the presence of a membrane potential ( $\Psi$ ) (**Figure 5a**, green  
circles). *HiSiaP* is required for transport since without external *HiSiaP* transport was negligible.  
304 These results agree with previous work on *HiSiaQM* purified in decyl- $\beta$ -D-maltoside (DM) (28) and  
show that our tagged construct is active and not inactivated by L-MNG. Net transport by *HiSiaQM*  
306 is electrogenic, as activity is enhanced when an inside negative membrane potential ( $\Psi$ ) is imposed  
(**Figure 5a**). Since Neu5Ac has a single negative charge at neutral pH, electrogenic transport means  
two or more Na<sup>+</sup> ions are transported for every Neu5Ac imported. Varying external [Na<sup>+</sup>] at a fixed  
308 substrate concentration resulted in a Hill coefficient of 2.9 (95% confidence interval = 2.2–3.9),  
implying that at least two Na<sup>+</sup> ions are co-transported during each transport cycle (**Figure 5b**). These  
310 data are consistent with the previous work (28), as well as the stoichiometry we recently determined  
for *PpSiaQM* (33).

312 The fused *HiSiaPQM* system appears to have a higher transport activity than the non-fused  
313 *PpSiaPQM* system. With the same experimental setup used for *PpSiaPQM* (5  $\mu$ M Neu5Ac, 50  $\mu$ M  
314 SiaP) (33), the accumulation of [ $^3$ H]-Neu5Ac by the fused *HiSiaPQM* is ~10-fold greater. Although  
315 this difference may reflect the reconstitution efficiency of each proteoliposome preparation, it is  
316 possible that it has evolved as a result of the origins of each transporter system—*P. profundum* is a  
317 deep-sea bacterium and as such the transporter is required to be functional at low temperatures and  
318 high pressures. In contrast, *H. influenzae* is mesophilic, found in the human respiratory tract and  
319 therefore more likely to show native-like rates in ambient experimental conditions. A similar pattern  
320 has been reported for the elevator transporter Glt<sub>Ph</sub>, where transporters from hyperthermophilic  
321 species are slow, and mesophilic versions are faster (55). These organisms also vary substantially in  
322 membrane lipid composition, which is currently too difficult to test in this experimental setup.

322 Next, we examined the *HiSiaQM* Na<sup>+</sup> binding sites in our cryo-EM structure (**Figure 5c**). The higher  
323 resolution antiparallel dimer structure shows density for Na<sup>+</sup> ions at both Na1 and Na2 sites  
324 (**Supplementary Figure 9a**), confirming the sites we identified and tested in *PpSiaQM* (33), and also  
325 the aforementioned stoichiometry of Na<sup>+</sup> ions transported determined in the *HiSiaQM*  
326 proteoliposome assay (28). The Na1 and Na2 sites across all four monomers are highly similar,  
327 although subtly different to those reported previously (**Supplementary Figure 9b**). The resolution  
328 of the structures allows for the unambiguous assignment of side chain positions at these binding sites  
329 and enables mechanistically important residues to be distinguished.

330 At the Na1 site, coordination is achieved by the backbone carbonyls of S298, G337, V340 and P342  
331 in a tetrahedral pattern, with a valence = 1, as determined by CheckMyMetal (56,57). The backbone  
332 carbonyl of S295 is also positioned for coordination but is slightly further away at 2.9/3.0  $\text{\AA}$ . In  
333 contrast, the equivalent carbonyl in *PpSiaQM* (S103) is closely associated with the Na<sup>+</sup> ion to form  
334 a trigonal bipyramidal coordination pattern. Na2 coordination is achieved by the backbone carbonyls  
335 of G517, G558 and M564, and the side chain hydroxyl of T561, which together coordinate the Na<sup>+</sup>  
336 ion in a tetrahedral pattern with a valence = 1.2/1.3. In contrast to the Na2 site of *PpSiaQM*, the  
337 backbone carbonyl of T561 is positioned further away at 4.2  $\text{\AA}$  distance and does not directly  
338 coordinate the Na<sup>+</sup> ion in our structure. In the *PpSiaQM* structure, the equivalent residue (T369)  
339 coordinates the Na<sup>+</sup> ion with both the side chain and main chain of T561 to form a square planar  
340 coordination pattern. S298, P342, G517 and G558 are highly conserved in TRAP transporters; S295,  
341 G337 and T561 sometimes vary as other small residues and V340 and M564 often vary as other  
342 hydrophobic side chains (**Supplementary Figure 8**). S298 did not show an effect on growth when  
343 mutated to alanine previously (27) and therefore may not be considered mechanistically important,

344 but our structure shows that it coordinates Na1 through the backbone carbonyl, masking the effect of  
the side chain mutation.

346 Our structures have a large cytoplasm-facing solvent-accessible cavity housing the putative binding  
site for Neu5Ac that is flanked by the Na1 and Na2  $\text{Na}^+$  ion sites (**Figure 5d**), similar to *PpSiaQM*.  
348 The dataset was collected without Neu5Ac and not surprisingly, there is no ligand density in the  
binding sites. The putative Neu5Ac binding site is lined with residues S300, A301, L302, P338,  
350 S343, I344, A345, I348, D521, A522, L523, Q526, T552, M555, M556, I559 and M566 of the  
352 transport domain which form a largely hydrophobic binding site (**Figure 5d**). This site is large  
enough to bind Neu5Ac and is more defined than previously reported (**Supplementary Figure 9c**)  
(27). Residues D304 and D521 each have a significant effect on bacterial growth when mutated to  
354 alanine and were thought to be involved in  $\text{Na}^+$  ion or substrate binding (27). Our structure shows  
356 that neither are involved in  $\text{Na}^+$  binding and although D521 does line the substrate binding pocket  
and introduces some charge to the site, D304 faces away from the substrate binding site and instead  
coordinates the residues that bind the  $\text{Na}^+$  ion at the Na1 site.

358 *On the formation of the tripartite complex.*

360 The observation that *HiSiaQM* can form a dimer has implications for the mechanism of transport,  
362 and as yet the affinity for the SiaP:SiaQM complex has not been directly established. To address this,  
364 we used analytical ultracentrifugation with fluorescence detection to determine the affinity between  
366 *HiSiaP* and *HiSiaQM* in the presence of Neu5Ac. Fluorescein isothiocyanate (FITC) was used to  
368 fluorescently label *HiSiaP*, with the labelling conditions adjusted to provide just one FITC label per  
370 *HiSiaP* protein. This allowed for a usable signal to be obtained at 10 nM *HiSiaP* and minimised any  
372 inhibitory effects on complex formation, as 22 of the 31 lysine residues of *HiSiaP* are spatially distant  
374 from the putative interacting surface. Titrating *HiSiaQM* in L-MNG to 40  $\mu\text{M}$  (a 4000-fold excess  
376 over *HiSiaP*, 10 nM) in the presence of 5 mM Neu5Ac resulted in the development of two peaks at  
~7.5 S and ~10.5 S (**Figure 6a**). Integration of the signal that shifted to a larger species resulted in  
~40% of the *HiSiaP* bound at the highest concentration of *HiSiaQM* (40  $\mu\text{M}$ ). This experiment  
allowed us to estimate a  $K_D$  for the complex of 65  $\mu\text{M}$  (95% confidence interval = 62–69  $\mu\text{M}$ , **Figure**  
**6b**). Avoiding non-ideality meant that we could only use concentrations of *HiSiaQM* approaching  
the  $K_D$ , but the binding model fit was very good ( $R^2 = 0.99$ ). This is in agreement with previous work  
that used surface plasmon resonance with biotin immobilised *HiSiaQM* in DDM, where a  $K_D$  of ~1  
 $\mu\text{M}$  was estimated, but it was stressed that the true  $K_D$  is very likely weaker due to the inability to fit  
a 1:1 binding model (27), which may have been complicated by the presence of dimeric *HiSiaQM* or  
aggregation.

## (Insert Figure 6)

378 Interestingly, the fluorescent signal shifted to two larger species. Based on the data for *HiSiaQM* in  
380 L-MNG (**Figure 3a**), the two species at ~7.5 S and ~10.5 S likely correspond to monomeric *HiSiaQM*  
382 with one *HiSiaP* monomer bound and dimeric *HiSiaQM* with either one or two *HiSiaP* monomers  
384 bound (**Figure 6a**). To support this stoichiometry, we checked the in-solution oligomeric state of  
*HiSiaP*, as there are examples of unusual TRAP substrate-binding proteins that form dimers (18,58). Both analytical ultracentrifugation (0.85 mg/mL, 25  $\mu$ M) and small angle X-ray scattering experiments (injected at 12.3 mg/mL, 360  $\mu$ M) suggest that *HiSiaP* is monomeric in solution (**Supplementary Figure 10**).

386 To understand the observed complex formation, the interaction between *HiSiaP* (PDB: 3B50) and  
388 *HiSiaQM* (PDB: 8THI) was modelled using AlphaFold2 (59). The predicted binding mode does  
390 allow two *HiSiaP* proteins to bind the parallel *HiSiaQM* dimer without significant steric clashes  
(**Supplementary Figure 11**) and each monomer has the same binding mode as the *PpSiaPQM* model  
(33).

392 The resolution of our structure enabled us to model the side chains and rationalise previous mutagenic  
394 experiments designed to define the SiaP:SiaQM interaction. We demonstrated that the periplasmic-  
396 facing residue R292 in *PpSiaM* is important for TRAP transporter activity and hypothesised that this  
398 residue is important for both the interaction with SiaP and rigidifying the scaffold-lateral arm helix  
400 junction (33). This residue is strictly conserved in sialic acid TRAP transporters but is not conserved  
402 across the TRAP transporter family (**Supplementary Figure 8**). Our structure shows that the  
404 equivalent residue in *HiSiaQM* (R484) adopts a similar solvent-accessible conformation and  
406 participates in an ionic interaction with D480, which in turn is interacting with K236  
408 (**Supplementary Figure 12**). Together these residues form a salt bridge network between two helices  
of the scaffold of the transporter. Consistent with this, mutation to R484E resulted in decreased  
bacterial growth, and reduced the binding of SiaP to SiaQM *in vitro* (27). Furthermore, mutations of  
residues on SiaP predicted to interact with this region reduce activity in both the *HiSiaPQM* (27) and  
*PpSiaPQM* (33) systems, highlighting the importance of this area for the transporter. It is clear that  
this region is important for SiaP recognition (also shown by the adjacent positioning of SiaP to this  
region in the complex model, **Supplementary Figure 11**) and may be further involved in modulating  
the conformational changes in SiaQM. Similarly, mutations R30E, S356Y and E429R all  
significantly reduced bacterial growth and SiaP binding (27). These mutations are consistent with  
disrupting the SiaP:SiaQM interaction as the residues are all solvent-accessible at the periplasmic  
surface of *HiSiaQM* in our structure and are close to *HiSiaP* in the complex model. All three residues

410 are strictly conserved across the TRAP transporter family (**Supplementary Figure 8**) and our  
411 structure shows that R30 (SiaQ) and E429 (SiaM) form a salt bridge (~2.5 Å) between two helices of  
412 the scaffold to connect SiaQ and SiaM, highlighting their structural significance (**Supplementary**  
413 **Figure 12**). Overall, the *HiSiaPQM* complex model is consistent with the mutagenesis of the  
414 *HiSiaPQM* and *PpSiaPQM* systems (27,33), but requires an experimental tripartite complex  
(SiaPQM) structure for validation.

416 Finally, the ability of related SiaPQM systems to substitute subunits was assessed using the transport  
417 assay (**Figure 5a**, **Figure 7a**). Two fused SiaPQM systems from the Pasteurellaceae family (*H.*  
418 *influenzae* and *Aggregatibacter actinomycetemcomitans*) were able to substitute the QM- and P-  
419 subunits and retain activity. With *HiSiaQM* in the proteoliposome, there was no transport when  
420 *PpSiaP* from the non-fused system was used (pink) but was fully functional when *AaSiaP* was used  
(blue). We also substituted the QM-subunits: with *AaSiaQM* in the proteoliposome, the transport  
421 was the same with *HiSiaP* and *AaSiaP* but slower in the *AaSiaPQM* system than *HiSiaPQM*,  
422 suggesting that differences in the mechanisms (e.g., the affinity of subunits or  $\text{Na}^+$ ) may exist even  
423 in systems similar enough to exchange subunits. That there was no transport with *HiSiaQM* and  
424 *PpSiaP* follows previous work demonstrating that SiaP from *V. cholerae* did not function with  
425 *HiSiaQM* (28). Structural analysis of the SiaP proteins from the fused and non-fused systems shows  
426 subtle differences in surface charge (**Figure 7b**), yet the activity results suggest the interacting  
427 surfaces have diverged enough to make them incompatible. It may also be that each system uses  
428 slightly different methods to engage the allosteric opening of SiaP.

430 **(Insert Figure 7)**

## Discussion

432 Using the well-studied *HiSiaPQM* TRAP as a model system (11,23,24,26-28), we: 1) determined a  
433 considerably higher resolution structure of the transmembrane subunits of this fused TRAP  
434 transporter, allowing us to now resolve side chains, lipids, the  $\text{Na}^+$  ion binding sites, and the substrate  
435 binding site; 2) demonstrate that *HiSiaQM* can form a dimeric configuration in maltoside detergents,  
436 amphipol and nanodiscs; and 3) determined the nature of the interaction between *HiSiaP* and  
437 *HiSiaQM* using biophysical methods. These experiments lead to many new conclusions that shape  
438 our understanding of how TRAP transporters function.

440 *The ‘elevator down’ (inward-facing) conformation is preferred in experimental conditions.* The two  
441 previous SiaQM structures have relied on the presence of a megobody for structure determination,  
442 which made contacts with the periplasmic surface of the transport domain. This interaction may

442 stabilise the protein in the observed ‘elevator down’ conformation. However, the dimeric structures  
444 we have presented have no other proteins bound, yet exist stably in the elevator down state, suggesting  
this is the most stable conformation in experimental conditions, where there is no membrane bilayer,  
membrane potential, or chemical gradient present.

446 *Lipids have strong interactions with HiSiaQM and are likely to be important for the transport*  
*mechanism.* The structure of the fused *HiSiaQM* confirms the presence of an extra transmembrane  
448 helix in the Q-subunit, compared to the non-fused TRAP systems that lack this helix. The extra  
450 transmembrane helix connects the small subunit to the large subunit via a short horizontal arm helix  
452 that runs parallel to the membrane. This horizontal helix is comprised of several positively charged  
454 residues that face the periplasm, contributing to an extra positive area on the surface of the transporter  
456 that is not seen in the non-fused *PpSiaQM*. The horizontal helix may act similarly to the two arm  
458 helices and improve transport by increasing the steadiness of the scaffold of the transporter. The  
high-resolution structure of *HiSiaQM* has identified well-defined lipids associated with tryptophan  
residues of the Q-subunits that form the dimer interface and a newly described single lipid in the  
binding pocket formed by the fusion helix. Both of these areas are likely important for anchoring the  
scaffold domain and allowing transport. As the single phospholipid is bound within the protein, it  
may also have a physiological role in P-subunit binding dynamics, as a mechanism of regulation  
depending on lipid type.

460 *HiSiaQM can exist as a monomer or a dimer.* We demonstrate that *HiSiaQM* can adopt both a  
monomeric and a dimeric configuration depending on the relative concentration of L-MNG detergent,  
462 with high concentrations favouring the monomer. This behaviour is characteristic of a self-  
association (**Supplementary Figure 1a, Figure 3a**). The formation of a stable dimeric species is  
464 also found in our amphipol structure, in other detergents, and in nanodiscs.

466 The parallel dimer is consistent with other elevator transporters, although the interface between the  
monomers is reduced. Notably, a related TAXI-TRAP transporter also appears to form a self-  
468 association (48) and the dicarboxylate transporter, VcINDY from *V. cholerae*, adopts a stable  
homodimeric configuration in crystal and in solution (38,39). VcINDY uses an elevator mechanism  
470 and cross-linking the dimer interface does not perturb transport, implying a lack of coupling between  
the monomers and an absence of large conformational changes at the interface (38). The dimerisation  
472 of VcINDY is used to stabilise the transport domains and allow the elevators to move up and down  
against the bound interface. Even with a small interface, a dimeric *HiSiaQM* assembly may further  
stabilise the scaffold of the two monomeric units.

474 The antiparallel dimer is hard to rationalise from a physiological standpoint. Although not

unprecedented *in vivo* with small bacterial multidrug transporters (60,61), an antiparallel structure makes little biological sense in the case of the TRAP transporter. In the antiparallel structure, the inverted monomer displays the cytoplasmic face towards the periplasm and will not bind SiaP, which is required for transport. This structure could result from removing the protein from its native environment, where it is constrained by the cell membrane, and in the absence of the constraints of the membrane can rotate around the interface when solubilised by detergents.

*The affinity of SiaP for SiaQM is weak.* For the SiaPQM TRAP transporter, the role of SiaP is to capture Neu5Ac with high affinity and deliver it to SiaQM before leaving to bind more Neu5Ac. As a result, a high-affinity SiaPQM complex that has a slow SiaP off-rate is likely not desired. Neither is a low-affinity SiaPQM complex that has a slow SiaP on-rate, as SiaQM relies on binding SiaP for transport (**Figure 5a**). The  $K_D$  observed in our experiments may be representative of a system with a fast off-rate (and potentially a fast on-rate) for SiaP. The resulting  $K_D$  is not of high affinity, but the transport cycle is optimised as SiaP quickly binds SiaQM, delivers Neu5Ac, and then leaves without getting ‘stuck’ to the transporter. The fast off-rate would reflect the conformational coupling of SiaP to SiaQM as the open state of SiaP that occurs after delivering Neu5Ac has been shown to bind SiaQM less (27).

The determined  $K_D$  may also reflect the experimental conditions. If the transporter is often in the conformation we observe to be stabilised in the structures, then the residues on the periplasmic surface of SiaQM may not be accessible or correctly positioned for binding with the partner residues on SiaP. In addition to the effects of detergent, the experimental conditions do not provide a  $\text{Na}^+$  gradient, which may have significant consequences on the positioning of SiaQM for interaction with SiaP. Under similar conditions, Peter et al. (27) estimated a comparable  $K_D$  of  $>1 \mu\text{M}$ , further indicating that the interaction affinity is low.

## 498 Conclusion

We have determined the oligomeric state of detergent solubilised *HiSiaQM* and the structure of amphipol solubilised *HiSiaQM* to near atomic resolution. In both membrane mimetics, we have observed a monomer-dimer self-association. The cryo-EM structure reveals the position of the extra transmembrane helix and shows that it is made of two sections with a positively charged periplasmic surface. This suggests that the extra helix may be involved in the interaction with SiaP, which has a predominantly negatively charged surface where it would likely bind the transporter. Furthermore, this work yields novel insights for drug design, as our structure can guide the design of inhibitors that block the SiaPQM interaction or use the system as a Trojan horse. In bacteria that rely solely on SiaPQM for obtaining Neu5Ac, such as *H. influenzae*, these inhibitors may have utility as

508 antibacterial agents.

## Materials and Methods

### 510 *Cloning of the substrate-binding protein, SiaP, and the membrane bound protein, SiaQM.*

512 The gene encoding SiaP from *H. influenzae* Rd KW20 was synthesised and cloned into the pET22b(+) vector to include a pelB leader sequence (Genscript). The pelB sequence signals the protein to the periplasm and is cleaved *in vivo* before purification. The gene encoding SiaQM from *H. influenzae* Rd KW20 was synthesised and cloned into the pBAD/HisA vector to include an N-terminal his-tag, 514 Xpress epitope, enterokinase cleavage site and a linker sequence (GeneArt, Thermo Fisher 516 Scientific). Full protein sequences for these genes are provided in **Supplementary Table 2**.

### *Expression and purification of the membrane embedded protein, SiaQM.*

518 *E. coli* TOP10 cells containing the pBAD/HisA\_HiSiaQM plasmid were grown in Terrific Broth medium in 1.5 L cultures at 37 °C to OD<sub>600</sub> = 1.4–1.8 before induction with 0.2% L-arabinose. 520 Induced cultures were incubated for 3 h at 37 °C and 180 rpm. Cells were harvested by centrifugation at 8000 g for 10 min at 4 °C, snap frozen and stored at -80 °C. Cells were thawed at room temperature 522 and added to resuspension buffer [1 x phosphate buffered saline (PBS) pH 7.4, 0.5 mg/mL lysozyme and 1 cOmplete protease inhibitor tablet (Roche) per 50 mL solution, or 1 mM phenylmethylsulfonyl 524 fluoride (PMSF)]. Cells were resuspended and then lysed by sonication (70% amplitude, 0.5 s on / 0.5 s off). Unbroken cells and cell debris were removed by centrifugation at 18,000 g for 25 min at 526 4 °C twice. Membranes were harvested by ultracentrifugation at 210,000 g for 2 h at 4 °C, snap-frozen and stored at -80 °C.

528 Membranes were resuspended in membrane resuspension buffer (1 x PBS pH 7.4, 1 mM PMSF, 5 mM dithiothreitol and 6% v/v glycerol). Once resuspended, 2% w/v L-MNG or DDM was added for 530 solubilisation for 2 h at 4 °C with gentle agitation. Insoluble material was removed by ultracentrifugation at 150,000 g for 1 h at 4 °C. The supernatant was collected, and imidazole was 532 added to a final concentration of 20 mM. The sample was applied to a HisTrap FF 5 mL column (Cytiva) equilibrated with buffer A (70 mM Tris pH 8, 150 mM NaCl, 20 mM imidazole, 6% v/v 534 glycerol, 5 mM β-mercaptoethanol (BME), 0.002–0.020% L-MNG (or 0.0348% DDM) and 0 or 5 mM Neu5Ac). The column was washed with 20 column volumes (CV) buffer A, then 10 CV 95% 536 buffer A and 5% buffer B (70 mM Tris pH 8, 150 mM NaCl, 500 mM imidazole, 6% v/v glycerol, 5 mM BME, 0.002–0.020% L-MNG (or 0.0348% DDM) and 0 or 5 mM Neu5Ac) before eluting the 538 protein with a gradient to 100% buffer B. Fractions identified by SDS-PAGE to contain *HiSiaQM* were pooled and concentrated. Concentrated protein was applied to a HiLoad 16/600 Superdex 200 540 pg size exclusion column (Cytiva) equilibrated in buffer C [50 mM Tris pH 8, 150 mM NaCl, 0.002–

0.020% L-MNG (or 0.0348% DDM) and 0 or 5 mM Neu5Ac]. The final purified protein was  
542 obtained at a yield of 0.5 mg/L of *E. coli* culture and was at least 95% pure by SDS-PAGE  
**(Supplementary Figure 1b).**

544 *Expression and purification of the substrate binding protein, SiaP.*

546 *E. coli* BL21 (DE3) cells containing the pET22b(+) *HiSiaP* plasmid were grown in M9 minimal  
548 medium with 0.1 mg/mL ampicillin in 1 L cultures at 26 °C to OD<sub>600</sub> = 0.3 before induction with 1  
mM IPTG. Induced cultures were incubated for 16 h at 26 °C and 180 rpm. Cells were harvested by  
548 centrifugation at 8,000 g for 10 min at 4 °C and resuspended in periplasmic extraction buffer [30 mM  
550 Tris pH 8, 20% w/v sucrose and 1 mM ethylenediaminetetraacetic acid (EDTA)] at room temperature  
(RT). The resuspension was incubated at RT for 10 min with shaking, then centrifuged at 13,000 g  
552 for 10 min at 4 °C. The supernatant was removed and the cell pellet rapidly resuspended in ice cold  
Milli-Q water. The resuspension was incubated for 10 min at 4 °C with shaking, then centrifuged as  
554 before. The supernatant was collected and PMSF was added to a concentration of 1 mM. The  
supernatant was filtered with a 0.2 µm filter and applied to a HiPrep Q FF 16/10 column (Cytiva)  
556 equilibrated in buffer D (50 mM Tris pH 8). The column was washed with 5 CV of buffer D before  
eluting the protein with a gradient to 100% buffer E (50 mM Tris pH 8, 1 M NaCl). SDS-PAGE was  
558 used to identify fractions containing *HiSiaP*. These fractions were pooled, and ammonium sulphate  
was added to a concentration of 1 M. The protein was applied to a HiPrep Phenyl FF 16/10 column  
560 (Cytiva) equilibrated in buffer F (50 mM Tris pH 8, 1 M ammonium sulphate). The column was  
washed with 5 CV of buffer F before eluting the protein with a gradient to 100% buffer G (50 mM  
562 Tris pH 8, 150 mM NaCl). SDS-PAGE was used to identify fractions containing *HiSiaP*. These  
fractions were pooled, concentrated, and applied to a HiLoad 16/600 Superdex 200 pg size exclusion  
564 column (Cytiva) equilibrated with buffer G. Fractions containing *HiSiaP* were pooled and  
concentrated for use in experiments. SDS-PAGE was used to visually assess purity.

566 *Reconstitution into nanodiscs.*

566 The membrane scaffold protein cNW11 [purchased from Now Scientific (Boston, USA)] was used  
568 for the reconstitution of *HiSiaQM* into nanodiscs. Lipid stocks of POPC (1-palmitoyl-2-oleoyl-  
glycero-3-phosphocholine) and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol) in  
chloroform were aliquoted in a 3:2 ratio and dried under nitrogen in a glass tube. The lipids were  
570 dissolved by heating and vortexing with buffer H (20 mM Tris pH 7.4, 100 mM NaCl, 0.5 mM EDTA  
and 160 mM sodium cholate). *HiSiaQM*, cNW11 and lipids were incubated together at the three ratios  
572 for 1 h on ice with a final cholate concentration between 25–27 mM. For empty nanodiscs, a similar

reconstitution was set up with only cNW11 and lipids. Bio-Beads SM-2 were added (0.5 g to each  
574 500  $\mu$ L reconstitution) and the solution was incubated on ice for another 30 min before gentle rotation  
576 for 16 h at 4 °C. The solution was removed from the Bio-Beads with a 24-gauge needle and spun at  
578 14,000 g to remove insoluble aggregates. The sample was concentrated and applied to a Superdex  
200 Increase 10/300 GL column equilibrated with buffer I (20 mM Tris pH 7.4, 100 mM NaCl and  
0.5 mM EDTA). Fractions of interest were concentrated and used for future experiments. SDS-PAGE  
was used to visually assess the presence of nanodisc reconstituted *HiSiaQM*.

580 *Reconstitution into amphipol.*

Amphipol A8-35 (Anatrace) was added at 5 mg per 1 mg purified *HiSiaQM* in L-MNG. Bio-Beads  
582 SM-2 were added at 100 mg per mL of the mixture before incubating overnight at 4 °C with gentle  
rotation. Following reconstitution, the amphipol bound protein was subjected to another size  
584 exclusion chromatography step, to remove unincorporated amphipol and any aggregated protein.  
Protein that eluted at a volume consistent with *HiSiaQM* was pooled, concentrated, and used in  
586 experiments.

*Western blotting.*

588 A western blot was used to verify the bands containing *HiSiaQM* on SDS-PAGE. *HiSiaQM* was  
separated by SDS-PAGE and transferred to nitrocellulose using NuPAGE transfer buffer + 20%  
590 methanol. The transfer was performed for 15 min at 15 volts. Membranes were blocked with Tris  
buffered saline + 0.1% Tween 20 (TBST) and 2% bovine serum albumin (BSA) for 1 h at 4 °C.  
592 Mouse Xpress IgG monoclonal antibody (Invitrogen) was diluted to 1/2500 in TBST + 2% BSA and  
incubated with the membranes overnight at 4 °C. Membranes were washed with water before  
594 incubating with rabbit anti-mouse IgG secondary antibody (Sigma-Aldrich) with conjugated alkaline  
phosphatase at 1/15000 in TBST + 2% BSA for 1 h at RT. Membranes were washed with TBST for  
596 five min, three times. Detection was performed by incubating the membranes with NBT/BCIP  
substrate solution (Thermo Fisher Scientific) for 10 min. The reaction was stopped by rinsing the  
598 membranes in water.

*Analytical ultracentrifugation.*

600 Sedimentation velocity experiments were performed in a Beckman Coulter XL-I AUC instrument  
unless otherwise stated. Samples were loaded into 12 mm double sector cells with sapphire windows,  
602 then mounted in an An-60 Ti rotor. Sedimentation data were analysed with UltraScan 4.0 (62,63).  
Optimisation was performed by two-dimensional spectrum analysis (2DSA) (64,65) with

604 simultaneous removal of time- and radially invariant noise contributions and fitting of boundary  
605 conditions. Where appropriate, 2DSA solutions were subjected to parsimonious regularisation by  
606 genetic algorithm analysis (66).

607 For determining the oligomeric state of *HiSiaQM*, the samples (0.40 mg/mL in L-MNG, 0.55 mg/mL  
608 in DDM) were in buffer G with either 20 times the critical micelle concentration (CMC) of L-MNG  
609 (0.02%, 200  $\mu$ M) or 4 times the CMC of DDM (0.0348%, 0.68 mM). Buffer density and viscosity  
610 values were measured with a density meter and microviscometer (Anton Paar). Radial absorbance  
611 data were collected at 280 nm, 42,000 rpm and 20 °C (L-MNG) or 4 °C (DDM). Oligomeric state  
612 and bound detergent calculations were performed using a method similar to Henrickson et al. (67),  
613 utilising sedimentation and diffusion coefficients obtained from UltraScan (62,63). These  
614 coefficients and the partial specific volumes of the detergents (L-MNG = 0.797 mL/g, DDM = 0.82  
615 mL/g) and protein (0.7634 mL/g) were used to calculate the masses of the detergent bound protein  
616 species.

617 For determining the *HiSiaQM* species in the nanodisc and amphipol samples, the methods used were  
618 similar to that above. The nanodisc samples were in buffer I. The data were collected at 280 nm,  
619 46,000 rpm and 10 °C. The amphipol sample was in buffer G. The data were collected at 0.27  
620 mg/mL, 280 nm (intensity data), 40,000 rpm and 20 °C in a Beckman Coulter Optima AUC  
instrument at the Canadian Center for Hydrodynamics at the University of Lethbridge.

621 For determining the oligomeric state of *HiSiaP*, the samples were in buffer G and buffer G + 5 mM  
622 Neu5Ac. Buffer density and viscosity values were estimated with UltraScan (62) or measured with  
623 a density meter and microviscometer (Anton Paar). The data were collected at 280 nm, 42,000 or  
624 50,000 rpm and 20 °C.

625 *Fluorescence detection analytical ultracentrifugation.*

626 Experiments were performed with FITC labelled *HiSiaP* and a concentration series of *HiSiaQM*. The  
627 FITC labelling was optimised to produce a ratio of 0.93 (~1) moles of FITC per mole of protein. A  
628 Beckman Coulter XL-A AUC instrument with a fluorescence detection system (AVIV Biomedical)  
629 was used with an An-50 Ti rotor at the University of Melbourne, Australia. To generate an artificial  
630 bottom, 50  $\mu$ L of FC43 fluorinert oil was loaded into the bottom of each cell. The samples (350  $\mu$ L)  
631 in buffer G + 0.002% L-MNG and 5 mM Neu5Ac were loaded into 12 mm double sector cells. *HiSiaP*  
632 was kept constant at 10 nM and *HiSiaQM* was varied across 14 concentrations (2-fold dilutions from  
633 40  $\mu$ M to 4.9 nM). The samples were incubated for an hour at room temperature, then run at 50,000  
634 rpm and 20 °C in fluorescence mode.

636 *Proteoliposome assays.*

Purified *HiSiaQM* was reconstituted using a batch-wise detergent removal procedure as previously described (54,68). In brief, 50  $\mu$ g of *HiSiaQM* was mixed with 120  $\mu$ L of 10% C<sub>12</sub>E<sub>8</sub> and 100  $\mu$ L of 10% egg yolk phospholipids (w/v) in the form of sonicated liposomes as previously described (69), 50 mM of K<sup>+</sup>-gluconate and 20 mM HEPES/Tris pH 7.0 in a final volume of 700  $\mu$ L. The reconstitution mixture was incubated with 0.5 g Amberlite XAD-4 resin under rotatory stirring (1,200 rev/min) at 25 °C for 40 min (69).

After reconstitution, 600  $\mu$ L of proteoliposomes were loaded onto a Sephadex G-75 column (0.7 cm diameter  $\times$  15 cm height) pre-equilibrated with 20 mM HEPES/Tris pH 7.0 with 100 mM sucrose to balance the internal osmolarity. Then, valinomycin (0.75  $\mu$ g/mg phospholipid) prepared in ethanol was added to the eluted proteoliposomes to generate a K<sup>+</sup> diffusion potential, as previously described (54). For a standard measurement, after 10 s of incubation with valinomycin transport was started by adding 5  $\mu$ M [<sup>3</sup>H]-Neu5Ac to 100  $\mu$ L proteoliposomes in the presence of 50 mM Na<sup>+</sup>-gluconate and 0.5  $\mu$ M of *HiSiaP*. Experiments were also performed varying the [Na<sup>+</sup>-gluconate] and SiaP species to determine their effect on transport. The transport assay was terminated by loading each proteoliposome sample (100  $\mu$ L) on a Sephadex G-75 column (0.6 cm diameter  $\times$  8 cm height) to remove the external radioactivity. Proteoliposomes were eluted with 1 mL 50 mM NaCl and collected in 4 mL of scintillation mixture, vortexed and counted. The radioactivity taken up in controls performed with empty liposomes, *i.e.*, liposomes without incorporated protein, was negligible with respect to the data obtained with proteoliposomes, *i.e.*, liposomes with incorporated proteins. All measurements are presented as means  $\pm$  SEM from independent experiments as specified in the figure legends. Data analysis and graphs of data and fit were produced using GraphPad Prism (version 9).

658 *Single particle cryogenic electron microscopy data collection, processing and map refinement.*

*HiSiaQM* was purified as before but with buffers containing a low concentration of L-MNG detergent (0.002%, 20  $\mu$ M) to produce a population favouring dimeric particles (see **Figure 2, blue trace**). The protein was exchanged into amphipol A8-35, concentrated, and frozen at -80 °C until use. The protein was thawed, centrifuged to remove any aggregates, concentrated to 4.1 mg/mL, applied to a glow-discharged (Gatan Solarus) Cu 2/1 carbon Quantifoil grid (Electron-microscopy Sciences), and blotted using a Vitrobot Mark IV (Thermo Fisher Scientific) for 3.5 s, at 4 °C, and with 100% humidity before vitrification in liquid ethane. The grid was screened for ice quality and particle distribution on a Talos Arctica microscope. A 14,281-image dataset was collected. The data collection parameters are provided in **Supplementary Table 1**.

668 All cryo-EM data processing was performed using CryoSPARC v.3.2.0 (70) (**Supplementary Figure**  
669 **2**). In brief, movie frames were aligned using patch motion correction with a B-factor of 500, and  
670 then contrast transfer function (CTF) estimations were made using the patch CTF estimation tool.  
671 Initially, 84,871 particles were picked from 295 micrographs using the Blob Picker tool and extracted.  
672 These particles were 2D classified into 50 classes, and 10 of these 2D classes were selected and used  
673 as a template for automated particle picking using the Template Picker tool, where 3,957,461 particles  
674 were picked from 14,281 micrographs. Particles were inspected with the Inspect Picks tool using an  
675 NCC Score Threshold of 0.1, and a Local Power range of 29,159 to 62,161. A total of 2,950,415  
676 particles were extracted with a box size of 400 pixels and Fourier cropped to 200 pixels. The extracted  
677 particles were then sorted using iterative rounds of 2D classification, where the best 39 classes  
678 showing some structural details were selected, retaining 618,442 particles. The particles were  
679 subjected to *ab initio* reconstruction separated into four classes. The two best 3D reconstructions  
680 represent dimers that oligomerised in two different ways—an antiparallel dimer and a parallel dimer,  
681 for which we had 225,044 and 220,810 particles, respectively. At this point, the datasets were  
682 separated for further processing. For each set of data, the reconstructions were used as a reference  
683 model for iterative rounds of non-uniform refinement, allowing a 2.99 Å map to be reconstructed for  
684 the antiparallel dimer and a 3.36 Å map to be reconstructed for the parallel dimer. For refinement of  
685 the antiparallel dimer, C2 symmetry was imposed. The final rounds of refinement were conducted  
686 using unbinned particles. The model was built using an initial model from AlphaFold (59), which  
687 was fit to the maps using Namdinator (71), ISOLDE (72) and Coot (73) were both used for further  
688 model building. A summary of the statistics for data processing, refinement, and validation is shown  
689 in **Supplementary Table 1**.

690 *Small-angle X-ray scattering.*

691 Small angle X-ray scattering data were collected on the SAXS/WAXS beamline equipped with a  
692 Pilatus 1 M detector (170 mm × 170 mm, effective pixel size, 172 μm × 172 μm) at the Australian  
693 Synchrotron. A sample detector distance of 1600 mm was used, providing a  $q$  range of 0.05–0.5 Å<sup>-1</sup>.  
694 *HiSiaP* (50 μL at 12.3 mg/mL) was measured in buffer G + 0.1% w/v NaN<sub>3</sub> and buffer I + 0.1% w/v  
695 NaN<sub>3</sub> and 5 mM Neu5Ac. Each sample was injected onto a Superdex 200 Increase 5/150 GL column  
696 (Cytiva) before data collection with 1 s exposures. Buffer subtraction and data analysis were  
697 performed in CHROMIXS and PRIMUS from the ATSAS program suite (74).

698 *Software.*

699 Molecular graphics and analyses were made with Pymol (75) and UCSF ChimeraX (76). Figures  
700 were made with Adobe Illustrator.

## Acknowledgements

702 This research was undertaken in part using the MX2 beamlines, and made use of the Australian  
704 Cancer Research Foundation (ACRF) detector, as well as the SAXS beamline at the Australian  
706 Synchrotron, part of ANSTO. R.A.N. and M.J.C. acknowledge the Canterbury Medical Research  
708 Foundation (CMRF) for Major Project Grant funding and the Biomolecular Interaction Centre (UC)  
710 for funding support. This research was supported by an AINSE Ltd. Postgraduate Research Award  
712 (PGRA) to M.J.C. and J.S.D. R.C.J.D. acknowledges the following for funding support, in part: 1)  
the Marsden Fund, managed by Royal Society Te Apārangī (contract UOC1506); 2) a Ministry of  
Business, Innovation and Employment Smart Ideas grant (contract UOCX1706); and 3) the  
Biomolecular Interaction Centre (UC). We thank Yee-Foong Mok and Amy Henrickson for their  
assistance with AUC experiments. Cryo-EM data were collected at the Cryo-EM Swedish National  
Facility funded by the Knut and Alice Wallenberg Foundation, the Family Erling Persson and Kempe  
Foundations, SciLifeLab, Stockholm University and Umeå University.

## 714 Competing interests

R.F. is currently employed by AstraZeneca.

716

## References

- 718 1. Ren, Q., and Paulsen, I. T. (2005) Comparative analyses of fundamental differences in  
membrane transport capabilities in prokaryotes and eukaryotes. *PLoS Comput Biol* **1**, e27
- 720 2. Pao, S. S., Paulsen, I. T., and Saier Jr, M. H. (1998) Major facilitator superfamily.  
*Microbiology and molecular biology reviews* **62**, 1-34
- 722 3. Reizer, J., Reizer, A., and Saier Jr, M. H. (1994) A functional superfamily of sodium/solute  
symporters. *Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes* **1197**, 133-  
166
- 724 4. Drew, D., North, R. A., Nagarathinam, K., and Tanabe, M. (2021) Structures and General  
Transport Mechanisms by the Major Facilitator Superfamily (MFS). *Chemical reviews* **121**,  
5289-5335
- 728 5. Bosshart, P. D., and Fotiadis, D. (2019) Secondary active transporters. *Bacterial Cell Walls  
and Membranes*, 275-299
- 730 6. Henriquez, T., Wirtz, L., Su, D., and Jung, H. (2021) Prokaryotic Solute/Sodium  
Symporters: Versatile Functions and Mechanisms of a Transporter Family. *International  
Journal of Molecular Sciences* **22**, 1880
- 732 7. Vimr, E. R. (2013) Unified theory of bacterial sialometabolism: how and why bacteria  
metabolize host sialic acids. *International Scholarly Research Notices* **2013**
- 734 8. Apicella, M. A. (2012) Nontypeable *Haemophilus influenzae*: the role of N-acetyl-5-  
neuraminic acid in biology. *Front Cell Infect Microbiol* **2**, 19
- 736 9. Cohen, M., and Varki, A. (2010) The sialome—far more than the sum of its parts. *Omics: a  
journal of integrative biology* **14**, 455-464
- 738 10. McDonald, N. D., Lubin, J.-B., Chowdhury, N., and Boyd, E. F. (2016) Host-derived sialic  
acids are an important nutrient source required for optimal bacterial fitness in vivo. *MBio* **7**,  
e02237-02215
- 740 11. Severi, E., Randle, G., Kivlin, P., Whitfield, K., Young, R., Moxon, R., Kelly, D., Hood, D.,  
and Thomas, G. H. (2005) Sialic acid transport in *Haemophilus influenzae* is essential for  
lipopolysaccharide sialylation and serum resistance and is dependent on a novel tripartite  
ATP-independent periplasmic transporter. *Mol Microbiol* **58**, 1173-1185
- 742 12. Allen, S., Zaleski, A., Johnston, J. W., Gibson, B. W., and Apicella, M. A. (2005) Novel  
sialic acid transporter of *Haemophilus influenzae*. *Infection and immunity* **73**, 5291-5300
- 744 13. Vimr, E., Lichtensteiger, C., and Steenbergen, S. (2000) Sialic acid metabolism's dual  
function in *Haemophilus influenzae*. *Mol Microbiol* **36**, 1113-1123
- 746 14. Jenkins, G. A., Figueira, M., Kumar, G. A., Sweetman, W. A., Makepeace, K., Pelton, S. I.,  
Moxon, R., and Hood, D. W. (2010) Sialic acid mediated transcriptional modulation of a  
highly conserved sialometabolism gene cluster in *Haemophilus influenzae* and its effect on  
virulence. *BMC Microbiol* **10**, 48
- 748 15. Bozzola, T., Scalise, M., Larsson, C. U., Newton-Vesty, M. C., Rovegno, C., Mitra, A.,  
Cramer, J., Wahlgren, W. Y., Radhakrishnan Santhakumari, P., Johnsson, R. E., Schwart, O.,  
Ernst, B., Friemann, R., Dobson, R. C. J., Indiveri, C., Schelin, J., Nilsson, U. J., and  
Ellervik, U. (2022) Sialic Acid Derivatives Inhibit SiaT Transporters and Delay Bacterial  
Growth. *ACS Chem Biol* **17**, 1890-1900
- 750 16. Kelly, D. J., and Thomas, G. H. (2001) The tripartite ATP-independent periplasmic (TRAP)  
transporters of bacteria and archaea. *FEMS microbiology reviews* **25**, 405-424
- 752 17. Rosa, L. T., Bianconi, M. E., Thomas, G. H., and Kelly, D. J. (2018) Tripartite ATP-  
independent periplasmic (TRAP) transporters and tripartite tricarboxylate transporters  
(TTT): from uptake to pathogenicity. *Frontiers in Cellular and Infection Microbiology* **8**, 33
- 754 18. Vetting, M. W., Al-Obaidi, N., Zhao, S., San Francisco, B., Kim, J., Wichelecki, D. J.,  
Bouvier, J. T., Solbiati, J. O., Vu, H., and Zhang, X. (2015) Experimental strategies for  
functional annotation and metabolism discovery: targeted screening of solute binding  
proteins and unbiased panning of metabolomes. *Biochemistry* **54**, 909-931

768 19. Mulligan, C., Fischer, M., and Thomas, G. H. (2011) Tripartite ATP-independent  
770 periplasmic (TRAP) transporters in bacteria and archaea. *FEMS microbiology reviews* **35**,  
68-86

772 20. Mulligan, C., Leech, A. P., Kelly, D. J., and Thomas, G. H. (2012) The membrane proteins  
774 SiaQ and SiaM form an essential stoichiometric complex in the sialic acid tripartite ATP-  
independent periplasmic (TRAP) transporter SiaPQM (VC1777–1779) from *Vibrio  
cholerae*. *Journal of Biological Chemistry* **287**, 3598-3608

776 21. Blum, M., Chang, H. Y., Chuguransky, S., Grego, T., Kandasamy, S., Mitchell, A., Nuka,  
778 G., Paysan-Lafosse, T., Qureshi, M., Raj, S., Richardson, L., Salazar, G. A., Williams, L.,  
Bork, P., Bridge, A., Gough, J., Haft, D. H., Letunic, I., Marchler-Bauer, A., Mi, H., Natale,  
780 D. A., Necci, M., Orengo, C. A., Pandurangan, A. P., Rivoire, C., Sigrist, C. J. A., Sillitoe,  
I., Thanki, N., Thomas, P. D., Tosatto, S. C. E., Wu, C. H., Bateman, A., and Finn, R. D.  
(2021) The InterPro protein families and domains database: 20 years on. *Nucleic Acids Res*  
**49**, D344-d354

782 22. Scheepers, G. H., Lycklama a Nijeholt, J. A., and Poolman, B. (2016) An updated structural  
classification of substrate-binding proteins. *FEBS letters* **590**, 4393-4401

784 23. Muller, A., Severi, E., Mulligan, C., Watts, A. G., Kelly, D. J., Wilson, K. S., Wilkinson, A.  
786 J., and Thomas, G. H. (2006) Conservation of structure and mechanism in primary and  
secondary transporters exemplified by SiaP, a sialic acid binding virulence factor from  
Haemophilus influenzae. *Journal of Biological Chemistry* **281**, 22212-22222

788 24. Johnston, J. W., Coussens, N. P., Allen, S., Houtman, J. C., Turner, K. H., Zaleski, A.,  
790 Ramaswamy, S., Gibson, B. W., and Apicella, M. A. (2008) Characterization of the *N*-  
792 acetyl-5-neuraminic acid-binding site of the extracytoplasmic solute receptor (SiaP) of  
nontypeable *Haemophilus influenzae* strain 2019. *Journal of Biological Chemistry* **283**, 855-  
865

794 25. Gangi Setty, T., Cho, C., Govindappa, S., Apicella, M. A., and Ramaswamy, S. (2014)  
Bacterial periplasmic sialic acid-binding proteins exhibit a conserved binding site. *Acta  
796 Crystallographica Section D: Biological Crystallography* **70**, 1801-1811

798 26. Fischer, M., Hopkins, A. P., Severi, E., Hawkhead, J., Bawdon, D., Watts, A. G., Hubbard,  
R. E., and Thomas, G. H. (2015) Tripartite ATP-independent Periplasmic (TRAP)  
798 Transporters Use an Arginine-mediated Selectivity Filter for High Affinity Substrate  
Binding. *J Biol Chem* **290**, 27113-27123

800 27. Peter, M. F., Ruland, J. A., Depping, P., Schneberger, N., Severi, E., Moecking, J.,  
802 Gatterdam, K., Tindall, S., Durand, A., Heinz, V., Siebrasse, J. P., Koenig, P.-A., Geyer, M.,  
Ziegler, C., Kubitscheck, U., Thomas, G. H., and Hagelueken, G. (2022) Structural and  
804 mechanistic analysis of a tripartite ATP-independent periplasmic TRAP transporter. *Nature  
Communications* **13**, 4471

806 28. Mulligan, C., Geertsma, E. R., Severi, E., Kelly, D. J., Poolman, B., and Thomas, G. H.  
808 (2009) The substrate-binding protein imposes directionality on an electrochemical sodium  
gradient-driven TRAP transporter. *Proceedings of the National Academy of Sciences* **106**,  
1778-1783

810 29. Lichtensteiger, C. A., and Virm, E. R. (1997) Neuraminidase (sialidase) activity of  
Haemophilus parasuis. *FEMS Microbiology Letters* **152**, 269-274

812 30. Vachon, V., Lyew, D. J., and Coulton, J. W. (1985) Transmembrane permeability channels  
814 across the outer membrane of *Haemophilus influenzae* type b. *Journal of bacteriology* **162**,  
918-924

816 31. Munson Jr, R., Brodeur, B., Chong, P., Grass, S., Martin, D., and Proulx, C. (1992) Outer  
Membrane Proteins PI and P2 of *Haemophilus influenzae* Type b: Structure and  
Identification of Surface-Exposed Epitopes. *Journal of Infectious Diseases* **165**, S86-S89

818 32. Wirth, C., Condemeine, G., Boiteux, C., Bernèche, S., Schirmer, T., and Peneff, C. M. (2009)  
NanC crystal structure, a model for outer-membrane channels of the acidic sugar-specific  
KdgM porin family. *Journal of molecular biology* **394**, 718-731

820 33. Davies, J. S., Currie, M. J., North, R. A., Scalise, M., Wright, J. D., Copping, J. M., Remus, D. M., Gulati, A., Morado, D. R., Jamieson, S. A., Newton-Vesty, M. C., Abeysekera, G. S., Ramaswamy, S., Friemann, R., Wakatsuki, S., Allison, J. R., Indiveri, C., Drew, D., Mace, P. D., and Dobson, R. C. J. (2023) Structure and mechanism of a tripartite ATP-independent periplasmic TRAP transporter. *Nature Communications* **14**, 1120

822 34. Punjani, A., and Fleet, D. J. (2021) 3D variability analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. *Journal of Structural Biology* **213**, 107702

824 35. Krissinel, E., and Henrick, K. (2007) Inference of Macromolecular Assemblies from Crystalline State. *Journal of Molecular Biology* **372**, 774-797

826 36. Gupta, K., Donlan, J. A. C., Hopper, J. T. S., Uzdavinys, P., Landreh, M., Struwe, W. B., Drew, D., Baldwin, A. J., Stansfeld, P. J., and Robinson, C. V. (2017) The role of interfacial lipids in stabilizing membrane protein oligomers. *Nature* **541**, 421-424

828 37. Chang, Y.-N., Jaumann, E. A., Reichel, K., Hartmann, J., Oliver, D., Hummer, G., Joseph, B., and Geertsma, E. R. (2019) Structural basis for functional interactions in dimers of SLC26 transporters. *Nature Communications* **10**, 2032

830 38. Mulligan, C., Fenollar-Ferrer, C., Fitzgerald, G. A., Vergara-Jaque, A., Kaufmann, D., Li, Y., Forrest, L. R., and Mindell, J. A. (2016) The bacterial dicarboxylate transporter VcINDY uses a two-domain elevator-type mechanism. *Nature structural & molecular biology* **23**, 256-263

832 39. Mancusso, R., Gregorio, G. G., Liu, Q., and Wang, D.-N. (2012) Structure and mechanism of a bacterial sodium-dependent dicarboxylate transporter. *Nature* **491**, 622-626

834 40. Nie, R., Stark, S., Symersky, J., Kaplan, R. S., and Lu, M. (2017) Structure and function of the divalent anion/Na<sup>+</sup> symporter from *Vibrio cholerae* and a humanized variant. *Nature communications* **8**, 1-10

836 41. Su, C.-C., Bolla, J. R., Kumar, N., Radhakrishnan, A., Long, F., Delmar, J. A., Chou, T.-H., Rajashankar, K. R., Shafer, W. M., and Edward, W. Y. (2015) Structure and function of *Neisseria gonorrhoeae* MtrF illuminates a class of antimetabolite efflux pumps. *Cell reports* **11**, 61-70

838 42. Bolla, J. R., Su, C.-C., Delmar, J. A., Radhakrishnan, A., Kumar, N., Chou, T.-H., Long, F., Rajashankar, K. R., and Edward, W. Y. (2015) Crystal structure of the *Alcanivorax borkumensis* YdaH transporter reveals an unusual topology. *Nature Communications* **6**, 1-10

840 43. Kaback, H. R. (2005) Structure and mechanism of the lactose permease. *Comptes rendus biologies* **328**, 557-567

842 44. Faham, S., Watanabe, A., Besserer, G. M., Cascio, D., Specht, A., Hirayama, B. A., Wright, E. M., and Abramson, J. (2008) The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na<sup>+</sup>/sugar symport. *Science* **321**, 810-814

844 45. Perez, C., Khafizov, K., Forrest, L. R., Krämer, R., and Ziegler, C. (2011) The role of trimerization in the osmoregulated betaine transporter BetP. *EMBO reports* **12**, 804-810

846 46. Yernool, D., Boudker, O., Jin, Y., and Gouaux, E. (2004) Structure of a glutamate transporter homologue from *Pyrococcus horikoshii*. *Nature* **431**, 811-818

848 47. Vergara-Jaque, A., Fenollar-Ferrer, C., Mulligan, C., Mindell, J. A., and Forrest, L. R. (2015) Family resemblances: A common fold for some dimeric ion-coupled secondary transporters. *J Gen Physiol* **146**, 423-434

850 48. Roden, A., Engelin, M. K., Pos, K. M., and Geertsma, E. R. (2023) Membrane-anchored substrate binding proteins are deployed in secondary TAXI transporters. *Biological Chemistry*

852 49. Nasr, M. L., Baptista, D., Strauss, M., Sun, Z.-Y. J., Grigoriu, S., Huser, S., Plückthun, A., Hagn, F., Walz, T., and Hogle, J. M. (2017) Covalently circularized nanodiscs for studying membrane proteins and viral entry. *Nature methods* **14**, 49-52

854 50. Nji, E., Chatzikyriakidou, Y., Landreh, M., and Drew, D. (2018) An engineered thermal-shift screen reveals specific lipid preferences of eukaryotic and prokaryotic membrane

872       proteins. *Nature Communications* **9**, 4253

874       51. Landreh, M., Marklund, E. G., Uzdavinys, P., Degiacomi, M. T., Coincon, M., Gault, J.,  
876       Gupta, K., Liko, I., Benesch, J. L. P., Drew, D., and Robinson, C. V. (2017) Integrating  
878       mass spectrometry with MD simulations reveals the role of lipids in Na<sup>+</sup>/H<sup>+</sup> antiporters.  
880       *Nature Communications* **8**, 13993

882       52. Matsuoka, R., Fudim, R., Jung, S., Zhang, C., Bazzone, A., Chatzikyriakidou, Y., Robinson,  
884       C. V., Nomura, N., Iwata, S., Landreh, M., Orellana, L., Beckstein, O., and Drew, D. (2022)  
886       Structure, mechanism and lipid-mediated remodeling of the mammalian Na<sup>+</sup>/H<sup>+</sup> exchanger  
888       NHA2. *Nature Structural & Molecular Biology* **29**, 108-120

890       53. de Jesus, A. J., and Allen, T. W. (2013) The role of tryptophan side chains in membrane  
892       protein anchoring and hydrophobic mismatch. *Biochimica et Biophysica Acta (BBA) -*  
894       *Biomembranes* **1828**, 864-876

896       54. Wahlgren, W. Y., Dunevall, E., North, R. A., Paz, A., Scalise, M., Bisignano, P., Bengtsson-  
898       Palme, J., Goyal, P., Claesson, E., and Caing-Carlsson, R. (2018) Substrate-bound outward-  
900       open structure of a Na<sup>+</sup>-coupled sialic acid symporter reveals a new Na<sup>+</sup> site. *Nature  
communications* **9**, 1-14

902       55. Huysmans, G. H. M., Ciftci, D., Wang, X., Blanchard, S. C., and Boudker, O. (2021) The  
904       high-energy transition state of the glutamate transporter homologue GltPh. *The EMBO  
Journal* **40**, e105415

906       56. Zheng, H., Chordia, M. D., Cooper, D. R., Chruscz, M., Müller, P., Sheldrick, G. M., and  
908       Minor, W. (2014) Validation of metal-binding sites in macromolecular structures with the  
910       CheckMyMetal web server. *Nat Protoc* **9**, 156-170

912       57. Brown, I. D. (2009) Recent developments in the methods and applications of the bond  
914       valence model. *Chem Rev* **109**, 6858-6919

916       58. Gonin, S., Arnoux, P., Pierru, B., Lavergne, J., Alonso, B., Sabaty, M., and Pignol, D.  
918       (2007) Crystal structures of an Extracytoplasmic Solute Receptor from a TRAP transporter  
920       in its open and closed forms reveal a helix-swapped dimer requiring a cation for alpha-keto  
922       acid binding. *BMC Struct Biol* **7**, 11

924       59. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O.,  
926       Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl,  
928       S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J.,  
930       Back, T., Petersen, S., Reiman, D., Clancy, E., Zielinski, M., Steinegger, M., Pacholska, M.,  
932       Berghammer, T., Bodenstein, S., Silver, D., Vinyals, O., Senior, A. W., Kavukcuoglu, K.,  
934       Kohli, P., and Hassabis, D. (2021) Highly accurate protein structure prediction with  
936       AlphaFold. *Nature* **596**, 583-589

938       60. Lloris-Garcerá, P., Bianchi, F., Slusky, J. S., Seppälä, S., Daley, D. O., and von Heijne, G.  
940       (2012) Antiparallel dimers of the small multidrug resistance protein EmrE are more stable  
942       than parallel dimers. *J Biol Chem* **287**, 26052-26059

944       61. Fluman, N., Tobiasson, V., and von Heijne, G. (2017) Stable membrane orientations of  
946       small dual-topology membrane proteins. *Proc Natl Acad Sci U S A* **114**, 7987-7992

948       62. Demeler, B., and Gorbet, G. E. (2016) Analytical Ultracentrifugation Data Analysis with  
950       UltraScan-III. in *Analytical Ultracentrifugation: Instrumentation, Software, and  
952       Applications* (Uchiyama, S., Arisaka, F., Stafford, W. F., and Laue, T. eds.), Springer Japan,  
954       Tokyo. pp 119-143

956       63. Dubbs, B., Zollars, D., Gorbet, G. E., Brookes, E. H., Savelyev, A., Mortezaee, S., and  
958       Demeler, B. UltraScan-III - a framework for hydrodynamic modeling.  
960       <https://github.com/ehb54/ultrascan3>.

962       64. Brookes, E. H., Boppana, R. V., and Demeler, B. (2006) Computing large sparse  
964       multivariate optimization problems with an application in biophysics. in *Proceedings of the  
966       2006 ACM/IEEE conference on Supercomputing*, Association for Computing Machinery,  
968       Tampa, Florida

970       65. Brookes, E., Cao, W., and Demeler, B. (2010) A two-dimensional spectrum analysis for

924 sedimentation velocity experiments of mixtures with heterogeneity in molecular weight and  
926 shape. *Eur Biophys J* **39**, 405-414

928 66. Brookes, E. H., and Demeler, B. (2007) Parsimonious regularization using genetic  
algorithms applied to the analysis of analytical ultracentrifugation experiments. in  
*Proceedings of the 9th annual conference on Genetic and evolutionary computation*,  
Association for Computing Machinery, London, England

930 67. Henrickson, A., Montina, T., Hazendonk, P., Lomonte, B., Neves-Ferreira, A. G. C., and  
Demeler, B. (2023) SDS-induced hexameric oligomerization of myotoxin-II from Bothrops  
asper assessed by sedimentation velocity and nuclear magnetic resonance. *European  
Biophysics Journal*

934 68. North, R. A., Wahlgren, W. Y., Remus, D. M., Scalise, M., Kessans, S. A., Dunevall, E.,  
Claesson, E., Soares da Costa, T. P., Perugini, M. A., and Ramaswamy, S. (2018) The  
936 sodium sialic acid symporter from *Staphylococcus aureus* has altered substrate specificity.  
*Frontiers in chemistry* **6**, 233

938 69. Scalise, M., Galluccio, M., Pochini, L., Console, L., Barile, M., Giangregorio, N., Tonazzi,  
940 A., and Indiveri, C. (2017) Studying interactions of drugs with cell membrane nutrient  
transporters: new frontiers of proteoliposome nanotechnology. *Current pharmaceutical  
design* **23**, 3871-3883

942 70. Punjani, A., Rubinstein, J. L., Fleet, D. J., and Brubaker, M. A. (2017) cryoSPARC:  
algorithms for rapid unsupervised cryo-EM structure determination. *Nature methods* **14**,  
944 290-296

946 71. Kidmose, R. T., Juhl, J., Nissen, P., Boesen, T., Karlsen, J. L., and Pedersen, B. P. (2019)  
Namdinator—automatic molecular dynamics flexible fitting of structural models into cryo-  
EM and crystallography experimental maps. *IUCrJ* **6**, 526-531

948 72. Croll, T. I. (2018) ISOLDE: a physically realistic environment for model building into low-  
resolution electron-density maps. *Acta Crystallogr D Struct Biol* **74**, 519-530

950 73. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of  
Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486-501

952 74. Manalastas-Cantos, K., Konarev, P. V., Hajizadeh, N. R., Kikhney, A. G., Petoukhov, M.  
V., Molodenskiy, D. S., Panjkovich, A., Mertens, H. D., Gruzinov, A., and Borges, C.  
954 (2021) ATSAS 3.0: expanded functionality and new tools for small-angle scattering data  
analysis. *Journal of Applied Crystallography* **54**

956 75. The PyMOL Molecular Graphics System, Version 2.1.1 Schrödinger, LLC.

958 76. Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I.,  
Morris, J. H., and Ferrin, T. E. (2021) UCSF ChimeraX: Structure visualization for  
researchers, educators, and developers. *Protein Sci* **30**, 70-82

960 77. Brautigam, C. A. (2015) Calculations and publication-quality illustrations for analytical  
ultracentrifugation data. *Methods in enzymology* **562**, 109-133

962 78. Ebel, C. (2011) Sedimentation velocity to characterize surfactants and solubilized  
membrane proteins. *Methods* **54**, 56-66

964 79. Le Maire, M., Arnou, B., Olesen, C., Georgin, D., Ebel, C., and Møller, J. V. (2008) Gel  
chromatography and analytical ultracentrifugation to determine the extent of detergent  
966 binding and aggregation, and Stokes radius of membrane proteins using sarcoplasmic  
reticulum Ca<sup>2+</sup>-ATPase as an example. *Nature protocols* **3**, 1782-1795

968 80. Le Roy, A., Wang, K., Schaack, B., Schuck, P., Breyton, C., and Ebel, C. (2015) AUC and  
small-angle scattering for membrane proteins. *Methods in enzymology* **562**, 257-286


970 81. Salvay, A. G., Santamaria, M., Le Maire, M., and Ebel, C. (2007) Analytical  
ultracentrifugation sedimentation velocity for the characterization of detergent-solubilized  
972 membrane proteins Ca<sup>++</sup>-ATPase and ExbB. *Journal of biological physics* **33**, 399-419

974 82. Lassmann, T. (2019) Kalign 3: multiple sequence alignment of large data sets.  
*Bioinformatics* **36**, 1928-1929


83. Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M., and Barton, G. J. (2009)

976 Jalview Version 2—a multiple sequence alignment editor and analysis workbench.  
*Bioinformatics* **25**, 1189-1191

978 84. Terwilliger, T. C., Sobolev, O. V., Afonine, P. V., and Adams, P. D. (2018) Automated map  
980 sharpening by maximization of detail and connectivity. *Acta Crystallogr D Struct Biol* **74**,  
545-559



**Figure 1 | An overview of Neu5Ac metabolism in *H. influenzae*.** 1) *H. influenzae* is sialidase negative and relies on environmental sialidases to hydrolyse and release terminal Neu5Ac from human glycoconjugates. 2) Outer membrane porins facilitate diffusion of Neu5Ac into the periplasm. 3) A mutarotase, NanM, catalyses the formation of  $\beta$ -Neu5Ac from  $\alpha$ -Neu5Ac to prepare for active transport across the inner membrane. 4) Neu5Ac is captured by the high-affinity substrate-binding protein, SiaP. SiaP delivers Neu5Ac to the SiaQM TRAP transporter, which uses a  $\text{Na}^+$  electrochemical gradient to drive transport. *H. influenzae* cannot synthesise Neu5Ac and relies solely on SiaPQM for obtaining environmental Neu5Ac. 5) Cytoplasmic processing of Neu5Ac by an isomerase, YhcH, generates the unfavourable open chain form in preparation for use by the first enzyme of the Neu5Ac degradation pathway, NanA. 6) Neu5Ac is sequentially degraded into cell wall constituents or fructose-6-phosphate, which can enter glycolysis. Five conserved enzymes (an aldolase, NanA; kinase, NanK; epimerase, NanE; deacetylase, NagA; and deaminase, NagB) are involved in this pathway which provides *H. influenzae* with carbon, nitrogen, and energy. 7) Alternatively, Neu5Ac can be activated by cytidine monophosphate and a sialic acid synthetase and added to lipooligosaccharides by a sialyltransferase. Definitions: Neu5Ac, *N*-acetylneuraminate; manNAc, *N*-acetylmannosamine; manNAc-6P, *N*-acetylmannosamine-6-phosphate; glcNAc, *N*-acetylglucosamine; glcNAc-6P, *N*-acetylglucosamine-6-phosphate; glcN-6P, glucosamine-6-phosphate; fru-6P, fructose-6-phosphate; galNAc, *N*-acetylgalactosamine; CMP, cytidine monophosphate; Omp, outer membrane porin; NanM, Neu5Ac mutarotase; YhcH, Neu5Ac isomerase; NanA, Neu5Ac lyase; NanK, manNAc kinase; NanE, manNAc-6P epimerase; NagA, glcNAc-6P deacetylase; NagB, glcN-6P deaminase.



1004

1006

1008

1010

1012


1014

1016


1018

1020


**Figure 2 | The structure of *HiSiaQM*.** **a**, Coulomb maps for the parallel (3.36 Å) and antiparallel (2.99 Å) *HiSiaQM* homodimers. The periplasmic surfaces of the monomers are facing the same direction for the parallel dimer (PDB: 8THI), whereas the periplasmic surface of one monomer is rotated 180° for the antiparallel dimer (PDB: 8THJ). The transport domain (orange and gold) is in the 'elevator down' conformation in all four monomers. The dimeric interface in both maps is distanced and neither has significant protein-protein interactions. The maps are coloured according to the topology in **c**. Density consistent with phospholipids is coloured grey and is particularly present in the dimer interface of the higher resolution antiparallel dimer map. **b**, Structural model of the *HiSiaQM* monomer. The transport domain is in the 'elevator down' conformation with the substrate binding site facing the cytoplasm. **c**, The topology of *HiSiaQM* is the same as the non-fused *PpSiaQM* with the addition of the fusion helix. The M-subunit forms the transport domain (orange and gold) and bracing arm helices (pink) as well as a large portion of the scaffold (purple and blue). The Q-subunit is entirely used as a scaffold for the elevator transport mechanism. The fusion helix (purple) connects the scaffold and adds to its size. It also forms a short horizontal helix, similar to the arm helices of the M-subunit. **d**, A structural overlay of *HiSiaQM* (2.9 Å structure, green; 4.7 Å structure, purple) and *PpSiaQM* (2.9 Å structure, orange) shows that the helices of the structures are well aligned, and all three structures are in the same conformation.




**Figure 3 | HiSiaQM self-association in L-MNG and amphipol. a**, SV-AUC analysis of *HiSiaQM* in L-MNG (left panel). Two well resolved species exist at 7.3 S (diffusion coefficient,  $D = 4.8 \times 10^{-7} \text{ cm}^2/\text{s}$ ) and 9.9 S ( $D = 4.2 \times 10^{-7} \text{ cm}^2/\text{s}$ ), with the larger peak constituting 85% of the signal. The species at 7.3 S (Peak 1, blue shading) is most consistent with *HiSiaQM* as a monomer with ~98 molecules of L-MNG bound (middle panel; green = measured mass, black = theoretical mass), calculated from the experimental sedimentation and diffusion coefficients. These calculations suggest that Peak 1 existing as a dimer is unlikely, as the dimeric protein would only have ~14 molecules of L-MNG bound. Additionally, the calculated  $f/f_0$  of a monomer for Peak 1 is 1.2, consistent with a protein in a detergent micelle. The species at 9.9 S (Peak 2, pink shading) is most consistent with *HiSiaQM* as a dimer with ~116 molecules of L-MNG bound (calculated) (right panel; purple = measured mass, black = theoretical mass); Peak 2 existing as a monomer is not possible, as the protein clearly has a smaller species in Peak 1 and cannot be divided further than a monomer, and a trimer is also unlikely as the trimeric protein would only have ~32 molecules of L-MNG bound (calculated). Additionally, the calculated  $f/f_0$  of a dimer for Peak 2 is also 1.2, again consistent with a protein in a detergent micelle. These calculations do not account for bound lipid molecules. **b**, Left panel, SV-AUC analysis of amphipol solubilised *HiSiaQM* (initially purified in L-MNG) shows two distinct species present at 5.9 S and 8.3 S. These are monomeric and dimeric species, as L-MNG solubilised protein exists as these oligomeric states at 7.3 S and 9.9 S as in **a**. Right panel, representative size exclusion chromatogram of amphipol solubilised *HiSiaQM* favouring the dimeric state. The main peak at ~10.8 mL contains dimeric *HiSiaQM* and the shoulder at ~11.8 mL contains monomeric *HiSiaQM*. The sample used for structure determination is shaded turquoise.



1044 **Figure 4 | Phospholipids bound to HiSiaQM.** **a**, The dimer has well-defined areas of density (grey)  
1046 that correspond to bound phospholipids. Two mechanistically important areas are the dimer interface  
1048 and fusion helix pocket. **b**, Phospholipids are present at the dimer interface, including in close contact  
1050 with the anchoring tryptophan residues (shown as spheres) of the Q-subunits that provide stability to  
the scaffold domain. **c**, A single phospholipid is trapped in a pocket formed by the fusion helix  
(protein model surface shown in colour, EM density in grey). The lipid is on the periplasmic side of  
the transporter and the headgroup appears to be coordinated by residues surrounding the top of the  
pocket, which have a generally positive character.




1052  
1054 **Figure 5 | Transport assays demonstrate that L-MNG solubilised *HiSiaQM* is functional.** **a**,  
1056  $[^3\text{H}]\text{-Neu5Ac}$  uptake was measured at multiple time intervals under each condition and used to  
1058 calculate transport rates. *HiSiaQM* had the highest activity in the presence of *HiSiaP*, a membrane  
1060 potential and a  $\text{Na}^+$  gradient (green circles). Approximately one-third of this rate was present without  
1062 a membrane potential (orange circles). Transport was low in the absence of  $\text{Na}^+$  (blue circles) and  
1064 negligible without *HiSiaP* (pink circles). Error bars represent the standard error of the mean (SEM)  
1066 for three technical replicates, except without *HiSiaP*, which has two replicates. The assay diagram  
1068 contains the parallel *HiSiaQM* structure, coloured by topology as in **Figure 2a,c**. This is for visual  
1070 presentation; it is not known if the transporter exists as a dimeric species in the assay. **b**, The rate of  
1072 transport is dependent on the concentration of  $\text{Na}^+$ , showing a sigmoidal response [Hill coefficient =  
1074 2.9 (95% C.I. 2.2–3.9)]. The  $K_m$  for  $\text{Na}^+$  is 12 mM (95% C.I. 10–14 mM). The displayed response  
shows that *HiSiaPQM* operates close to its maximum measured rate at a reasonably low external  $\text{Na}^+$   
concentration (25 mM). Error bars represent the SEM of five technical replicates. **c**, Two  $\text{Na}^+$  binding  
sites (Na1 and Na2) were identified in *HiSiaQM*. These sites share highly similar coordinating  
residues with *PpSiaQM*. At the Na1 site, a  $\text{Na}^+$  ion (grey) is coordinated by the carbonyl groups of  
S298, G337, V340 and P342 (orange sticks, coordination shown as black dashes). S295 is also shown  
but its carbonyl is positioned just outside the coordination distance in our structure. At the Na2 site,  
a  $\text{Na}^+$  ion (grey) is coordinated by the carbonyl groups of G517, G558 and M564, and the side chain  
hydroxyl of T561 (gold sticks, coordination shown as black dashes). **d**, A putative substrate binding  
site (SBS, outlined) is located in the transport domain of *HiSiaQM* (orange and gold). The mostly  
hydrophobic binding site (shown as sticks and electrostatic surface) exists between the two  $\text{Na}^+$   
binding sites and is large enough to bind Neu5Ac.



1076 **Figure 6 | Sedimentation velocity AUC analysis of the interaction between *HiSiaQM* and *HiSiaP*** in L-MNG detergent. **a**, Titrating increasing concentrations of *HiSiaQM* (blue, 40  $\mu$ M (2.88 mg/mL); pink, 20  $\mu$ M; green, 10  $\mu$ M; brown, 5  $\mu$ M; other concentrations omitted for clarity) against fluorescently labelled FITC-*HiSiaP* (10 nM) identifies a shift in the signal for *HiSiaP* from 3 S to ~7.5 S and ~10.5 S. This shift demonstrates binding to *HiSiaQM* and identifies two bound species with different sedimentation coefficients. The two species are annotated with the most likely binding stoichiometries (one or two *HiSiaP* monomers (red and grey) may be binding the dimeric species). **b**, Fitting a binding model to the data (Fraction bound =  $[P]_{\text{total}} / [P]_{\text{total}} + K_D$ ) estimates a  $K_D$  of 65  $\mu$ M (95% confidence interval = 62–69  $\mu$ M,  $R^2 = 0.99$ ).

1078  
1080  
1082  
1084



1086

**Figure 7 | Subunit substitution transport assays.** **a**, Transport was measured with subunit substitution of *HiSiaPQM* with the fused SiaPQM from *A. actinomycetemcomitans* (*Aa*) and the non-fused SiaPQM from *P. profundum* (*Pp*). Transport activity was measured in the presence of a membrane potential and a  $\text{Na}^+$  gradient. The mean activity is shown as bars with SEM error from at least three technical replicates ( $n = 3$  or 4). **b**, Electrostatic surface comparison of the putative SiaQM interaction surfaces of *HiSiaP*, *AaSiaP* and *PpSiaP*. The SiaP proteins of the two fused systems have a greater area of negatively charged residues (red, circled) at the N-terminal lobe than in the non-fused system.

1088

1090

1092

1094